RESUMEN
A plethora of prolonged COVID-19 symptoms, or late manifestations has been reported after acute disease and labeled "post-COVID". The aim of this study was to identify the prevalence of and risk factors for post-COVID up to 12 weeks after the onset of acute COVID-19. An electronic survey was conducted to evaluate post-COVID-19 symptoms, disease severity, demographics, and pre-existing diseases. The participants were recruited through 88,648 SMS messages, and post on social media. The associations between variables were explored through multivariate models. From 6,958 respondents with confirmed COVID-19, 753 (10.8%) required hospitalization, and 5,791 (83.2%) exhibited at least one post-COVID manifestation. Hair loss (49.4%), memory loss (40.7%), low attention (37.0%), fatigue (34.2%), anxiety (31.2%), and headache (29.6%) were the most reported post-COVID manifestations. Female sex, myalgia, anosmia, and severe disease were associated with most post-COVID manifestations. Pre-existing depression was associated with the development of neuropsychiatric manifestations. Post-COVID manifestations were identified in most patients following COVID-19 infection, placing a supplementary burden on the healthcare system. Hair loss, fatigue, and neuropsychiatric symptoms were the most prevalent post-COVID manifestations. Female sex, myalgia, anosmia, and more severe disease are risk factors for multiple post-COVID manifestations.
Asunto(s)
COVID-19 , Síndrome Post Agudo de COVID-19 , Femenino , Humanos , Alopecia , Anosmia , Brasil/epidemiología , COVID-19/epidemiología , Fatiga , Mialgia , Prevalencia , Factores de Riesgo , Síndrome Post Agudo de COVID-19/epidemiología , Trastornos de la MemoriaRESUMEN
Interest has increased in comorbidities associated with psoriasis and their effects on health-related quality of life (HRQoL). This study aimed to evaluate the prevalence of metabolic syndrome (MetS) and psoriatic arthritis (PsA) and to investigate HRQoL and the prevalence of hypertension, type 2 diabetes mellitus (T2DM), obesity and dyslipidemia. In a cross-sectional design, patients diagnosed with plaque psoriasis answered an interview and standardized questionnaires (Dermatology Life Quality Index questionnaire [DLQI], 36-Item Short Form Health Survey [SF-36] and EuroQol Five-Dimension Questionnaire Three-Level version [EQ-5D-3L]). Physical examination and several tests to assess desired outcomes were performed by a dermatologist and a rheumatologist during three visits. The prevalence of MetS and PsA was 50.0% and 41.8%, respectively. Dyslipidemia was the most prevalent (74.5%) secondary comorbidity, followed by hypertension (61.8%), obesity (52.5%) and T2DM (30.9%). The mean (standard deviation) DLQI score was 6.5 (6.9), and mean physical and mental SF-36 measures were 45.2 (10.4) and 45.5 (12.3), respectively, and for EQ-5D-3L, mean utility index and EQ-VAS scores were 0.68 (0.27) and 72.7 (19.7), respectively. PsA and MetS are important comorbidities; a reduced HRQoL is noted among plaque psoriasis patients with these comorbidities, emphasizing the relevance of diagnosis and treatment beyond the care of skin lesions.
Asunto(s)
Artritis Psoriásica/epidemiología , Síndrome Metabólico/epidemiología , Psoriasis/epidemiología , Calidad de Vida , Adulto , Brasil/epidemiología , Comorbilidad , Estudios Transversales , Diabetes Mellitus Tipo 2/epidemiología , Dislipidemias/epidemiología , Femenino , Humanos , Hipertensión/epidemiología , Masculino , Persona de Mediana Edad , Obesidad/epidemiología , Prevalencia , Índice de Severidad de la Enfermedad , Encuestas y CuestionariosRESUMEN
Objetivo: O objetivo do estudo foi determinar aprevalência de doenças alérgicas em uma amostra depacientes com vitiligo segmentar e não-segmentar. Métodos: Foram estudados retrospectivamente 261pacientes com vitiligo no período entre 2000 e 2004 eanalisadas as características clínicas e prevalência dedoenças alérgicas. Resultados: Identificamos freqüência maior de rinite alérgica, perene ou sazonal, em pacientes com vitiligo segmentar (37,50 per cent vs 19,91 per cent, p= 0,014). Verificamos provavelmente os primeiros casos de asma em pacientes com vitiligo segmentar em literatura indexada. Conclusões: Nossos resultados não confirmam a maior prevalência de doenças alérgicas em pacientes com vitiligo comparado a outros estudos que analisaram a população em geral.